FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387476951> ?p ?o ?g. }

• W4387476951 endingPage "2742" @default.
• W4387476951 startingPage "2742" @default.
• W4387476951 abstract "Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with few treatment options. A promising TNBC treatment approach is targeting the oncogenic signaling pathways pivotal to TNBC initiation and progression. Deregulated activation of signal transducer and activator of transcription 3 (STAT3) is fundamental to driving TNBC malignant transformation, highlighting STAT3 as a promising TNBC therapeutic target. Methoxyhispolon Methyl Ether (MHME) is an analog of Hispolon, an anti-cancer polyphenol found in the medicinal mushroom Phellinus linteus. Still, MHME’s anti-cancer effects and mechanisms remain unknown. Herein, we present the first report about MHME’s anti-TNBC effect and its action mechanism. We first revealed that MHME is proapoptotic and cytotoxic against human TNBC cell lines HS578T, MDA-MB-231, and MDA-MB-463 and displayed a more potent cytotoxicity than Hispolon’s. Mechanistically, MHME suppressed both constitutive and interleukin 6 (IL-6)-induced activation of STAT3 represented by the extent of tyrosine 705-phosphorylated STAT3 (p-STAT3). Notably, MHME-evoked apoptosis and clonogenicity impairment were abrogated in TNBC cells overexpressing a dominant-active mutant of STAT3 (STAT3-C); supporting the blockade of STAT3 activation is an integral mechanism of MHME’s cytotoxic action on TNBC cells. Moreover, MHME downregulated BCL-2 in a STAT3-dependent manner, and TNBC cells overexpressing BCL-2 were refractory to MHME-induced apoptosis, indicating that BCL-2 downregulation is responsible for MHME’s proapoptotic effect on TNBC cells. Finally, MHME suppressed SRC activation, while v-src overexpression rescued p-STAT3 levels and downregulated apoptosis in MHME-treated TNBC cells. Collectively, we conclude that MHME provokes TNBC cell apoptosis through the blockade of the SRC/STAT3/BCL-2 pro-survival axis. Our findings suggest the potential of applying MHME as a TNBC chemotherapy agent." @default.
• W4387476951 created "2023-10-11" @default.
• W4387476951 creator A5001072359 @default.
• W4387476951 creator A5006607834 @default.
• W4387476951 creator A5013515321 @default.
• W4387476951 creator A5034025409 @default.
• W4387476951 creator A5046217092 @default.
• W4387476951 creator A5058621099 @default.
• W4387476951 creator A5059203305 @default.
• W4387476951 creator A5066547264 @default.
• W4387476951 creator A5079766589 @default.
• W4387476951 date "2023-10-10" @default.
• W4387476951 modified "2023-10-16" @default.
• W4387476951 title "Methoxyhispolon Methyl Ether, a Hispolon Analog, Thwarts the SRC/STAT3/BCL-2 Axis to Provoke Human Triple-Negative Breast Cancer Cell Apoptosis In Vitro" @default.
• W4387476951 cites W1964703598 @default.
• W4387476951 cites W1987388371 @default.
• W4387476951 cites W2014853719 @default.
• W4387476951 cites W2026073532 @default.
• W4387476951 cites W2028544780 @default.
• W4387476951 cites W2038693071 @default.
• W4387476951 cites W2066696169 @default.
• W4387476951 cites W2074356752 @default.
• W4387476951 cites W2074741551 @default.
• W4387476951 cites W2139975046 @default.
• W4387476951 cites W2286160951 @default.
• W4387476951 cites W2555414266 @default.
• W4387476951 cites W2760867582 @default.
• W4387476951 cites W2793670714 @default.
• W4387476951 cites W2895446525 @default.
• W4387476951 cites W2906052725 @default.
• W4387476951 cites W2913584903 @default.
• W4387476951 cites W2946899637 @default.
• W4387476951 cites W2955977137 @default.
• W4387476951 cites W2962551393 @default.
• W4387476951 cites W2970480621 @default.
• W4387476951 cites W3036353607 @default.
• W4387476951 cites W3047583541 @default.
• W4387476951 cites W3049036781 @default.
• W4387476951 cites W3105073783 @default.
• W4387476951 cites W3108835271 @default.
• W4387476951 cites W3156985612 @default.
• W4387476951 cites W3192991259 @default.
• W4387476951 cites W4206548876 @default.
• W4387476951 cites W4207050061 @default.
• W4387476951 cites W4286250866 @default.
• W4387476951 cites W4293776771 @default.
• W4387476951 cites W4304084160 @default.
• W4387476951 cites W4313331609 @default.
• W4387476951 cites W4313505510 @default.
• W4387476951 cites W4386742223 @default.
• W4387476951 doi "https://doi.org/10.3390/biomedicines11102742" @default.
• W4387476951 hasPublicationYear "2023" @default.
• W4387476951 type Work @default.
• W4387476951 citedByCount "0" @default.
• W4387476951 crossrefType "journal-article" @default.
• W4387476951 hasAuthorship W4387476951A5001072359 @default.
• W4387476951 hasAuthorship W4387476951A5006607834 @default.
• W4387476951 hasAuthorship W4387476951A5013515321 @default.
• W4387476951 hasAuthorship W4387476951A5034025409 @default.
• W4387476951 hasAuthorship W4387476951A5046217092 @default.
• W4387476951 hasAuthorship W4387476951A5058621099 @default.
• W4387476951 hasAuthorship W4387476951A5059203305 @default.
• W4387476951 hasAuthorship W4387476951A5066547264 @default.
• W4387476951 hasAuthorship W4387476951A5079766589 @default.
• W4387476951 hasBestOaLocation W43874769511 @default.
• W4387476951 hasConcept C121608353 @default.
• W4387476951 hasConcept C126322002 @default.
• W4387476951 hasConcept C171958077 @default.
• W4387476951 hasConcept C185592680 @default.
• W4387476951 hasConcept C190283241 @default.
• W4387476951 hasConcept C2778923194 @default.
• W4387476951 hasConcept C2780110267 @default.
• W4387476951 hasConcept C502942594 @default.
• W4387476951 hasConcept C530470458 @default.
• W4387476951 hasConcept C55493867 @default.
• W4387476951 hasConcept C71924100 @default.
• W4387476951 hasConcept C86803240 @default.
• W4387476951 hasConceptScore W4387476951C121608353 @default.
• W4387476951 hasConceptScore W4387476951C126322002 @default.
• W4387476951 hasConceptScore W4387476951C171958077 @default.
• W4387476951 hasConceptScore W4387476951C185592680 @default.
• W4387476951 hasConceptScore W4387476951C190283241 @default.
• W4387476951 hasConceptScore W4387476951C2778923194 @default.
• W4387476951 hasConceptScore W4387476951C2780110267 @default.
• W4387476951 hasConceptScore W4387476951C502942594 @default.
• W4387476951 hasConceptScore W4387476951C530470458 @default.
• W4387476951 hasConceptScore W4387476951C55493867 @default.
• W4387476951 hasConceptScore W4387476951C71924100 @default.
• W4387476951 hasConceptScore W4387476951C86803240 @default.
• W4387476951 hasIssue "10" @default.
• W4387476951 hasLocation W43874769511 @default.
• W4387476951 hasOpenAccess W4387476951 @default.
• W4387476951 hasPrimaryLocation W43874769511 @default.
• W4387476951 hasRelatedWork W1993520606 @default.
• W4387476951 hasRelatedWork W1995630420 @default.
• W4387476951 hasRelatedWork W2058861111 @default.
• W4387476951 hasRelatedWork W2358007372 @default.
• W4387476951 hasRelatedWork W2362355507 @default.

• next